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Abstract
Background: Cancer growth, invasion and metastasis are highly related to tumor-associated
neovasculature. The presence and progression of endothelial cells in cancer is chaotic, unorganized,
and angiogenic vessels are less functional. Therefore, not all markers appearing on the chaotic
endothelial cells are accessible if a drug is given through the vascular route. Identifying endothelial
cell markers from functional cancer angiogenic vessels will indicate the accessibility and potential
efficacy of vascular targeted therapies.
Results: In order to quickly and effectively identify endothelial cell markers on the functional and
accessible tumor vessels, we developed a novel technique by which tumor angiogenic vessels are
labeled in vivo followed by Laser Capture Microdissection of microscopically isolated endothelial
cells for genomic screening. Female C3H mice (N = 5) with established SCCVII tumors were
treated with Rhodamine-RCA lectin by tail vein injection, and after fluorescence microscopy
showed a successful vasculature staining, LCM was then performed on frozen section tissue using
the PixCell II instrument with CapSure HS caps under the Rhodamine filter. By this approach, the
fluorescent angiogenic endothelial cells were successfully picked up. As a result, the total RNA
concentration increased from an average of 33.4 ng/ul +/- 24.3 (mean +/- S.D.) to 1913.4 ng/ul +/-
164. Relatively pure RNA was retrieved from both endothelial and epithelial cells as indicated by
the 260/280 ratios (range 2.22–2.47). RT-PCR and gene electrophoresis successfully detected
CD31 and Beta-Actin molecules with minimal Keratin 19 expression, which served as the negative
control.
Conclusion: Our present study demonstrates that in vivo Rhodamine RCA angiogenic vessel
labeling provided a practical approach to effectively guide functional endothelial cell isolation by
laser capture microdissection with fluorescent microscopy, resulting in high quality RNA and pure
samples of endothelial cells pooled for detecting genomic expression.
Background
The advent of laser capture microdissection (LCM) tech-
nology has remarkably advanced cancer research. Devel-
oped in a collaborative effort between the National
Institutes of Health and Arcturus Engineering in 1996,
LCM has served as an invaluable tool for separating tumor
cells from normal tissue within heterogeneous neoplasms
to better characterize their differences [1,2]. By microscop-
ically extrapolating intact tissue with a simple pulse of a
low-power infrared laser, the "captured" cells are adhered
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to a thermoplastic cap. These representative samples then
provide a snapshot into the mechanisms occurring in the
microtumor environment, permitting the analysis of bio-
logical molecules such as RNA and DNA, which remain
structurally uncompromised during the microdissection
process [3]. Thereafter, LCM derived cells can be exam-
ined using downstream assays such as polymerase chain
reaction (PCR) and quantitative, real-time PCR, providing
much insight into the regulatory pathways observed
within proliferating cancer cells. Several studies have uti-
lized LCM to conduct molecular analysis of pure isolated
cells from breast, ovarian, prostate and squamous cell car-
cinomas [4-8]. As a result, the application of LCM in
research has created genomic and proteomic expression
profiles and many cell-specific markers have been identi-
fied [9].
An innovative approach to cancer therapy has focused on
angiogenic targeting of molecular markers on the luminal
surface of tumor vasculature to promote tumor regression
[10-13]. Proliferating endothelial cells are the prime tar-
gets of vascular targeting agents (VTAs) utilized for con-
trolling angiogenesis, the process by which new blood
vessels are formed [14]. For this purpose, efforts to classify
and characterize tumor vasculature, specifically neovascu-
lature, has prompted close examination of mosaic blood
vessels, circulating endothelial cells and endothelial cell
precursors [15]. These endothelial modalities integrate
into new and existing blood vessels. In comparison to
cancer cells, which develop resistance to anticancer
agents, endothelial cells are of special interest and serve as
better targets because they are less likely to mutate[16].
Angiogenesis researchers have extensively investigated the
effects of naturally occurring antigens such as Alpha-V
Beta-3 and vascular permeability factor (VEGF) on cell
regulation. These inducers of angiogenesis which mediate
numerous functions of endothelial cells including prolif-
eration, migration, invasion, survival, and permeability
have proven to be useful therapeutic targets for diseases
characterized by neovascularization. Monoclonal anti-
body targeting as well as angiogenesis inhibitors have
been utilized in clinical studies to cut off blood supply to
targeted cells in tumors [17,18]. With this in mind, the
application of laser capture microdissection is an ideal
method for studying the effects of angiogenic inhibitors,
identifying cell surface antigens for antibody targeting and
discovering new biomarkers on tumor endothelium at
molecular and genetic levels.
Typically, researchers have utilized immunohistochemi-
cal (IHC) and fluorescent staining against specific markers
for endothelial cells such as von Willebrand Factor (VWF),
CD34, CD31 and Ricinus communis agglutinin I (RCA) lec-
tin to identify tumor vasculature and guide the laser cap-
ture microdissection process [19-22]. To date, several
studies have focused on optimizing staining protocols to
reduce the processing time of samples for LCM because
evidence supports the notion that there is a direct correla-
tion between RNA degradation and factors such as length
of tissue processing time and exposure to RNases during
sample preparation [23-25]. Murakami et al. reported that
exposure to aqueous media for an extended period of
time, a requirement of traditional immunohistochemical
staining, could "destroy 99% of the mRNA" from a sam-
ple [26]. While rapid immunohistochemical and fluores-
cent staining can effectively label endothelial cells in vitro,
these pathological tools are limited by their inability to
identify and distinguish between functional and accessi-
ble tumor vasculature.
Therefore, we developed a novel methodology for intrave-
nously labeling cancerous endothelial cells with fluores-
cent Rhodamine RCA lectin to guide LCM. By this
approach, in vivo labeling circumvents the aforemen-
tioned technical issues while effectively identifying func-
tional tumor vessels that are accessible if a drug was given
via the vascular route. This method of endothelium labe-
ling has not been previously combined with laser capture
microdissection and provides a roadmap for molecular
targeting in endothelial cells. Moreover, in vivo labeling
of angiogenic vessels provides a practical technique for
discovering surrogate markers of angiogenesis and a clin-
ically relevant strategy for vascular targeted therapies. The
objective of this study was to demonstrate the efficacy and
compatibility of endothelial cell in vivo labeling with
RCA lectin to further guide LCM for mRNA detection and
quantitation. Here, we verify the reliability of RCA lectin




SCCVII, a murine squamous cell carcinoma cell line was
kindly provided by Dr. Anastasia Sowers (Radiation
Oncology Branch, National Cancer Institute, Bethesda,
MD, USA) and cultured at 37°C with 5% CO2 in RPMI
1640 medium (Biofluids, Gaithersburg, MD, USA) con-
taining 10% fetal calf serum, 2 mM L-glutamine, and pen-
icillin-streptomycin (BioSource International; Rockville,
MD, USA), 50 IU ml-1 and 50 μg ml-1 respectively.
2) Animal model and RCA in vivo labeling of tumor 
angiogenic vessels
Female C3H mice (6–9 weeks) were purchased from
Charles River Laboratories (Gaithersburg, MD, USA) and
subjected to S.C. inoculation. All animal work was per-
formed according to an approved animal protocol and in
compliance of NIH Clinical Center Animal Care and Use
Committee guidelines. A suspension of SCCVII cells (1 ×Molecular Cancer 2006, 5:5 http://www.molecular-cancer.com/content/5/1/5
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106 cells in 100 μl of PBS) was injected in the left flank of
five mice with a 27 G needle. The inoculated mice were
monitored daily for growth of the tumors; the tumor vol-
ume being measured every second day using calipers. On
average, a tumor required 7–10 days to grow to 0.4 cm3 in
volume when the tissue was ready for harvesting. Techni-
cally, in vivo labeling of the functional tumor vasculature
was performed via tail-vein injection of Rhodamine Rici-
nus communis agglutinin I (RCA) (Vector Laboratories, CA,
USA) and allowed to circulate for 5 min before the mice
were euthanized. Immediately after the mice were sacri-
ficed, the tumors were harvested, quickly frozen on dry ice
and stored in -80°C until processing.
3) RNAase free sample preparation
To prevent any contamination of RNases, the Leica Cryo-
stat Instrument was cleaned with 100% ethanol and a new
disposable blade was replaced prior to sectioning the
tumor samples. Each frozen tumor sample was removed
from the cryovial using clean forceps, immediately
embedded in OCT medium (Thermo Shandon, PA, USA)
and allowed to equilibrate to the cryostat temperature of -
21°C. Fifty tissue sections for each of the five samples
were sectioned at 7 μm, placed on Histogene™ LCM Slides
(Arturus, CA, USA) and directly fixed in fresh cold acetone
(+4°C) for 2 minutes. Two slides per LCM session were
completely dehydrated in sterile jars (Evergreen Scientific,
CA, USA) containing RNAase free reagents provided in the
Histogene Dehydrations Kit (Arturus, CA). Each slide was
placed in solutions of 75% ethanol-30 sec, 95% ethanol-
30 sec, 100% ethanol-30 sec, and Xylene- 5 minutes
respectively and allowed to dry for five minutes on a hor-
izontal staining rack.
4) Laser capture microdissection
RNase free conditions were maintained by wiping the Pix-
Cell II LCM system (Arturus, CA, USA) stage and work
areas surrounding the instrument with RNase Away.
Immediately following dehydration, the tissue was exam-
ined under fluorescent microscopy to detect the successful
tumor angiogenic vessel staining under the Rhodamine
filter. Then, the parameters were established for selection
and excision of endothelial cells with at least a 6 μm diam-
eter. In order to achieve a laser spot size smaller than 7.5
μm, which is the minimum size reported by Arcturus, we
determined that a power setting of 40 mW and duration
of 450 μs was sufficient. Only the vessels propagating flu-
orescence were chosen and pulsed by the manually
maneuvered laser spot. By this approach, fluorescent
labeled vessels were detached from the slide and lifted
onto a thermoplastic polymer film on the high sensitivity
(HS) Cap. Within a one hour time frame per slide, we
were able to collect approximately 150–200 endothelial
cells per sample. Epithelial cells were also microdissected
under the following laser conditions: 15 μm spot size,
power 50 mW and at 2.0 W duration. Four HS caps, gen-
erating a total of 600–800 endothelial cells for each of the
five tissue samples were collected and pooled to generate
an adequate concentration of RNA for downstream analy-
sis.
5) RNA analysis and quality assessment
Processing of the total RNA began immediately following
LCM. Extraction, isolation and two rounds of amplifica-
tion were performed using the PicoPure RNA Isolation Kit
(Arcturus, CA, USA) and the RiboAmp HS RNA Amplifi-
cation Kit (Arcturus, CA, USA) respectively, according to
the manufacturer's recommendations. Exactly 10 μl of
extraction buffer was added to the ExtractSure device, in
which the samples remained on the HS cap positioned
upright in the heating block. Each aperture was covered
with a 0.5 ml- Eppendorf tube (Arcturus, CA, USA) and
incubated at 42°C for 30 min, followed by centrifugation
at 800 × g for two minutes. At that point, all endothelial
cell pooled samples were combined for isolation, and a
net yield of 11 μl was quantified using UV Spectropho-
tometry with Ribogreen Fluorescence. Next, mRNA was
generated after two rounds of amplification.
6) Reverse transcription-polymerase chain reaction
First strand cDNA was synthesized with the Promega
Reverse Transcription System according to the manufac-
turer's recommendations. The reverse transcription reac-
tion was primed with random primers, starting from
5'end throughout the length of the RNA. The first of the
two 10 μl mixtures were prepared containing 2 μl of RNA
sample, denatured at 70°C to prevent secondary binding,
and 8 μl DEPC treated water. The second mixture con-
sisted of 4 μl MgCL2, 2 μl RT 10 × Buffer, 2 μl dNTP, 0.5
RNase inhibitor, 1 μl AMV RT Transcriptase and 0.5 μl
random primers. Both mixtures were combined and
reverse transcription was conducted at the following set-
tings: 20°C ~10 min, 42°C~45 min, 95°C ~5 min, and
4°C ~∞ in the AB9700 Thermocycler. (Applied Biosys-
tems, CA, USA). Thereafter, cDNA was stored at -20°C
overnight.
7) Polymerase chain reaction
Three microliters of cDNA was combined with a 47 μl
PCR mix consisting of 5 μl 10 × buffer, 1 μl DNTP, 0.3 μl
TAQ polymerase, 38.7 μl Ultra Pure Water and 1 μl from
each set of primers. Messenger RNA sequences for CD31,
KER19, Beta-Actin were custom designed for our experi-
mentation to determine the purity of the LCM samples.
Beta Actin primers as P1: 5'CGTGGGCCGCCCTAG-
GCACCA-3', P2: 5'-TTGGCCTTAGGGTTCAGGGGGG-3';
CD31 primers: P1 5'-GTGCTCTATGCAAGCCTCCA-3',
P2: 5'-TTCGAGGTGGTGC TGATGTC-3', and Mouse
Cytokeratin 19 primers P1: 5'-TG GGCAGATTGTTGTTAT-
GGA-3', P2: 5'-TCAGGGCAGTAATTTCCTCC-3' as seen inMolecular Cancer 2006, 5:5 http://www.molecular-cancer.com/content/5/1/5
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table 1. The PCR Core Kit was utilized to synthesize
dsDNA sequenced at 60 cycles at 94°C ~30 sec, 55°C ~30
sec and 72°C for 45 sec for denaturation, primer anneal-
ing and extension of annealed primers respectively.
Results and discussion
Identifying functional tumor vasculature for LCM with 
RCA-I lectin
Intravascular labeling and immunohistochemical stain-
ing of endothelial cells with lectin are relatively estab-
lished methods. Ricinus communis agglutinin I (RCA-I),
Ulex europaeus agglutinin-I (UEA-I) and Wheat germ
agglutinin (WGA) have been recognized as practical mark-
ers for endothelial cells in intact tissue and cell culture.
Gerhart et al. reported strong staining of RCA-I in vessels
of canine cerebral cortex and capillaries bound to luminal
membrane of endothelial cells [27]. Their results indi-
cated that lectin receptors were distributed continuously
along the endothelial membrane. Likewise, Chang et al.
utilized Rhodamine- RCA lectin as a perfusion marker to
identify functional blood vessels in Enhanced Green Flu-
orescent Protein (EGFP) expressing tumors [28]. Equally
important, their feasible and reliable technique of intrave-
nously labeling endothelium provided no evidence of
RCA lectin in vivo labeling is an effective way to mark functional angiogenic vessels Figure 1
RCA lectin in vivo labeling is an effective way to mark functional angiogenic vessels. SCCVII tumors were systemi-
cally labeled with Rhodamine-RCA Lectin and 7 μm tissue sections were counterstained with DAPI and observed under 40× 
objective upright microscope (Zeiss, USA) through Rhodamine and DAPI filters. (scale bar = 50 um) A: Endothelial cell nuclei 
staining pattern observed with bright blue DAPI counterstain in SCCVII neoplasm. B: Functional angiogenic vessels labeled by 
tail vein injection of Rd-RCA lectin. RCA-I is able to successfully stain endothelial cells due to the specific affinity to beta D-
galactose which is found on the luminal surface of blood vessels. C: Merged signals of vessels and the cell nuclear staining by 
DAPI. The abundance of nuclei present in the tissue is not representative of the functional and accessible tumor vasculature in 
the merged image.
Table 1: mRNA custom designed primer sequences for polymerase chain reaction analysis of angiogenic endothelial cells isolated from 
SCCVII mouse model neoplasms.
Gene Sense sequence Anti-sense sequence
GADPH P1 5'-ACCACAGTCCATGCCATCAC-3' P2 5'-TCCACCACCCTGTTGCTGTA-3'
Beta Actin P1 5'-CGTGGGCCGCCCTAGGCACCA-3' P2 5'-TTGGCCTTAGGGTTCAGGGGGG-3'
CD31 P1 5'-GTGCTCTATGCAAGCCTCCA-3' P2 5'-TTCGAGGTGGTGCTGATGTC-3'
P3 5'-ATGGAATTCCCCATTGAGGC-3' P4 5'-GATTTCAAACTTGGGAGTGG-3'
P5 5'-TTCTGAACTCCAACAGCGAG-3' P6 5'-AGGCTCAAGGGAGGACACTT-3'
P7 5'-TGCCGAAGGCCCAAAGAAGA-3' P8 5'-GCTCAGACCTTAGGAAACCG-3'
Keratin 19 P1 5'-TGGGCAGATTGTTGTTATGGA-3' P2 5'-TCAGGGCAGTAATTTCCTCC-3'
P3 5'-CCTGGCTGCAGATGACTTCA-3' P4 5'-AGACGGAGGCCCGTTATGGA-3'
P5 5'-TAAAACTTCCACCGCGGACT-3' P6 5'-TTCCTATAGCTATCGCCAGA-3'
Alpha V P1 5'-CTCTGAATCTGCCGTCAGT-3' P2 5'-GCCAAGTGCTTGCAGATCAC-3'
P3 5'-GTGATGTTAGTGGTGACTAG-3' P4 5'-AAGGTTGACCTCGCCGAAAG-3'
Beta 3 P1 5'-CTGTTACAATATGAAGAATG-3' P2 5'-TTTTCATCACATACTGTAGC-3'
P3 5'-ACTGTGCCTGCCAGGCCTTT-3' P4 5'-TCCTTGGGGCTGCACTCTTC-3'Molecular Cancer 2006, 5:5 http://www.molecular-cancer.com/content/5/1/5
Page 5 of 11
(page number not for citation purposes)
nonperfused vessels. Systemic RCA-I labeling of func-
tional tumor vasculature utilizes targeted lectin-carbohy-
drate based interactions to identify receptors uniquely
expressed on endothelial cell surfaces. For these reasons,
we modeled this method of systemic injection for labeling
functional and angiogenic tumor vessels to guide laser
capture microdissection. As a result, we successfully
observed all accessible and functional endothelial cells
labeled with RCA-I under fluorescent microscopy.
Significance of in vivo labeling of tumor vasculature
A new technique in vascular targeting, such as physically
isolating host endothelium, is an ideal strategy for discov-
ering molecular markers with tumor specificity. Our
present study was founded on the hypothesis that the phe-
notypes of in vivo labeled endothelial cells and IHC
stained endothelial cells are distinct. Although RCA lectin
immunohistochemical staining could successfully label
the tumor vasculature, not all vessels expressing endothe-
lial markers are accessible to drugs administered systemi-
cally. Consequently, immunohistochemical staining
would yield remote gene profiling, unrepresentative to
that of the proliferating cells. The significance of in vivo
labeling was demonstrated by comparing the quantity of
functional tumor vasculature identified by systemic injec-
tion of RCA versus IHC staining. As seen in Figure 1A, a
plethora of DAPI stained nuclei was observed in the
tumor, however, an overlapping image of RCA-I labeled
vessels within the same tissue (Figure 1C) revealed that
the vast number of nuclei detected by IHC was not repre-
sentative of the few functional vessels present in the
tumor section.
Laser capture microdissection of functional endothelial 
cells
While LCM provides a simplistic yet comprehensive
approach for isolating select cells from a variety of tissue
types, procurement of endothelial cells can be quite chal-
lenging. There are several technical issues that must be
considered when optimizing LCM protocols to microdis-
sect mouse endothelium. First, in order for LCM to work
effectively the targeted endothelial cells must be distin-
guished from surrounding epithelium to yield a homoge-
nous cell population. This matter was addressed by
intravenously labeling the tumor vasculature with RCA-I
lectin (Figure 2A). Second, modifications to the laser spot
size were necessary to avoid extracting adjacent pericytes,
which are also present in capillary walls. Since, tumor ves-
sels vary in diameter from 1–8 μm and the smallest stand-
ard spot size for the LCM instrument is 7 μm, we adjusted
the laser spot according to a reported method for control-
ling the spot size [29,30]. By decreasing the laser power,
we precisely removed thin tumor vasculature from the
host environment (Figure 2B, 2C). The third concern
involved generating enough tissue samples on each cap to
retrieve sufficient mRNA for downstream assays. Due to
the limitations of the laser spot size, only 2–3 cells were
captured per laser pulse.
Successful Rd-RCA I lectin guided capture of endothelial cells under inverted 40× magnification Figure 2
Successful Rd-RCA I lectin guided capture of endothelial cells under inverted 40× magnification. A: Fluorescent 
labeled angiogenic and functional vessels are distinguished from the surrounding epithelium prior to performing LCM. B: A 
low-powered infrared laser was pulsed over the targeted cells, which expanded the film on the cap and extracted the entire 
vessel. C: An intact vessel containing a homogeneous cell population generated for molecular analysis. The presence of RCA-
Rhodamine labeled endothelial cells on the "cap" image and the absence of the targeted cells in the "after" microdissection 
image confirmed successful capture. A power setting of 40 mW and duration of 450 μs were utilized to obtain a 5.0–6.0 μm 
diameter laser spot size, which permitted precise selection of endothelium using the Pix Cell II Instrument.Molecular Cancer 2006, 5:5 http://www.molecular-cancer.com/content/5/1/5
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Consequently, it was necessary to pool four caps to pro-
duce an adequate concentration of starting total RNA for
each of the five endothelial cell samples as described by
Zhang et al [31]. Overall, the optimized protocol permit-
ted successful extraction of SCCVII mouse model
endothelial cells.
Determining the quality and concentration of RNA
The BioAnalyzer provided a general quality assessment of
the LCM derived samples; however we relied on the Nan-
oDrop to provide a more precise measurement of the RNA
extract's optical density. The electropherogram in Figure 3
confirmed that the amplified RNA was of good quality
Assessment of RNA integrity in frozen sections of mouse SCCVII tumor tissue Figure 3
Assessment of RNA integrity in frozen sections of mouse SCCVII tumor tissue. The Agilent BioAnalyzer system 
determined that the RNA from two-round amplification of endothelial and epithelial cell samples had comparable concentra-
tion of 1278.5 ng/μl. The spectra clearly indicated the presence of a marker peak and a broad hump in the electropherogram 
confirming good RNA quality. Further mRNA analysis demonstrated a high quality starting sample of total RNA by the 260/280 
ratio for the five endothelial and epithelial cell samples. Moreover, the RNA quality and concentration was comparable to that 
of the control sample.Molecular Cancer 2006, 5:5 http://www.molecular-cancer.com/content/5/1/5
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The purity of endothelial cell RNA pool is measured by RT-PCR amplification of endothelial cell marker CD31, squamous cell  carcinoma epithelial specific gene Keratin 19 as well as the Beta-Actin housekeeping gene from LCM samples Figure 4
The purity of endothelial cell RNA pool is measured by RT-PCR amplification of endothelial cell marker CD31, 
squamous cell carcinoma epithelial specific gene Keratin 19 as well as the Beta-Actin housekeeping gene from 
LCM samples. Approximately 200 endothelial cells as well as control epithelial cells were microdissected and captured from 
each sample RNA was extracted and then amplified. In order to verify the quality and purity of the LCM endothelial RNA sam-
ples, custom designed primers for house keeping gene Beta-Actin, CD31D, and two pairs of Keratin 19 (KER19A, KER19 B) 
were applied to the pool by RT-PCR. The results indicated that the endothelial pool does not contain Keratin 19 mRNA, 
which is expressed in the epithelial pool.Molecular Cancer 2006, 5:5 http://www.molecular-cancer.com/content/5/1/5
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characterized by a broad hump. Contrarily, a spectrum of
contaminated samples would display sharp peaks with
high background and short integration time. The fluores-
cence reading revealed that the concentration of amplified
epithelial cells exceeded that of the endothelial cell sam-
ple, which was understandable considering the large vari-
ation in the laser spot size when performing LCM. Since
epithelial cells in cancer tissue are relatively abundant and
easier to extract, we used a larger laser spot size to collect
these samples. For experimentation purposes, the epithe-
lial cells only served as a control to determine the purity
of the endothelial cells. Therefore, epithelial cell concen-
tration at this level of analysis was not a major factor. A
Ribogreen Low Range Calibration was performed to
detect the amount of nucleic acid present in the isolated
vessel tissues.
The initial RNA concentration of microdissected samples
was compared to the final sample concentration after per-
forming two-round amplification. As a result cap pooling
and amplification, the total RNA concentration increased
from 33.4 ng/μl ± 24.3 (mean ± S.D.) to 1913.4 ng/μl ±
164 in the endothelial cell samples. Relatively pure RNA
was retrieved from endothelial and epithelial cells as indi-
cated by the 260/280 ratios (range 2.22–2.47). Exactly, 1
μl sample from all five samples of endothelial cells
yielded a mean ratio of 2.25. Similarly, the mean ratio for
the five epithelial cell samples was 2.21. Ratios lower than
1.8–2.0 are indicative of contamination. These results
were comparable to that of the control samples (N = 5),
which had a mean total RNA concentration of 1987.06
ng/μl ± 27.8 and an average 260/280 ratio of 2.58.
We performed two-step RT-PCR, in which the RT reaction
and PCR were sequentially conducted, utilizing two dif-
ferent sets of primers during the RT and PCR steps (Table
1). Random primers were used for general amplification
throughout the mRNA template, followed by PCR with
several pairs of gene-specific primers. Expression of CD31
in the LCM-derived endothelial cells was detected by RT-
PCR in addition to using Beta-Actin as an internal control.
Expression of Beta-Actin was conserved after two rounds
of amplification. The absence of Keratin in the endothelial
sample validated the accuracy of our technique, demon-
strating that we extracted a pure endothelial cell sample.
PCR products were visualized in a 2% agarose gel stained
with ethidium bromide (Figure 4). In contrast, the epithe-
lial cells showed positive Keratin expression Keratin,
although it was downregulated. The low expression of
Keratin in our epithelial sample may be attributed to the
uniqueness of the cancer cell line used in the study. Our
results were consistent with findings from the literature
which reveal that Cytokeratin 19 is highly expressed in
normal epithelium; however squamous cell carcinomas
exhibit patchy negative staining [32]. Ultimately, the
RT-PCR amplification of housekeeping genes and CD31  endothelial cell markers from LCM derived cells Figure 5
RT-PCR amplification of housekeeping genes and 
CD31 endothelial cell markers from LCM derived 
cells. About 200 endothelial cells were microdissected and 
captured, the RNA was extracted and amplified. After first 
strand cDNA synthesis, primers designed for murine CD31 
RT-PCR mCD31a: 5'TTCTGAACTCCAACAGCGAG-3', 
5'-AGGCTCAAGGGAGGACACTT-3'; mCD31b: 5'-
TGCCGAAGGCCCAAAGAAGA-3', 5'GCTCAGACCT-
TAGGAAACCG-3, GAPDH and β-Actin were detected by 
PCR.Molecular Cancer 2006, 5:5 http://www.molecular-cancer.com/content/5/1/5
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endothelial cells displayed upregulation of CD31 expres-
sion with minimal contamination.
Significance of antibodies
While intravenous labeling of endothelium established
that the targeted tumor vasculature was functional, still
the angiogenic nature of the captured vessels had to be
determined. For this purpose, we utilized gel electro-
phoresis to detect the presence of Alpha-V Beta-3 integrin.
Alpha-V Beta-3 is a protein that is upregulated in various
pathological conditions including tumors associated with
angiogenic endothelial cells. In order to measure the sen-
sitivity of our method, we selected CD31 as an endothelial
marker and Keratin 19 as the epithelial cell marker. Posi-
tive immunohistochemical staining of CD31 in figure 4
confirmed that it was an excellent cell marker for endothe-
lial cell recognition. Also, Keratin 19, which is a squamous
cell carcinoma epithelium marker served as the negative
control and indicated epithelial contamination in LCM-
derived probes [33]. Success of the compatibility of the in
vivo labeling with laser capture microdissection was ulti-
mately determined by the quality of mRNA retrieved from
the LCM derived samples, expression of CD31 and house
keeping genes Beta-Actin and GADPH. The absence of
Keratin 19 in the endothelial cells demonstrated little or
no contamination in the endothelial cell sample.
Study limitations
The application of our in vivo labeling technique may be
challenged by the fact that shortly after systemic adminis-
tration of Rd-RCA lectin the mice were euthanized. Still,
neither the perfusion of vessels or specificity of lectin
binding to the tumor endothelium was affected by this
procedure. Also, the toxicity of lectin is a major concern
when considering the practicality of our in vivo labeling
method for clinical application. We show unambiguous
evidence that the moderate toxicity of RCA-I does not
denature or alter the genetic material within the labeled
and microdissected vasculature. Specifically, systemic
RCA lectin labeling of tumor vasculature detected anti-
bodies that are notably found in endothelial cells. Moreo-
ver, we demonstrated that endothelial cell phenotypes in
SCCVII mouse model tumors can be discriminated by lec-
tin binding.
Integrin Beta 3 and CD31 are highly expressed in the SCCVII tumor angiogenic vessels detected by RT-PCR from laser capture  microdissected endothelial cells and confirmed by immunohistochemical staining of Integrin Beta-3 Figure 6
Integrin Beta 3 and CD31 are highly expressed in the SCCVII tumor angiogenic vessels detected by RT-PCR from 
laser capture microdissected endothelial cells and confirmed by immunohistochemical staining of Integrin Beta-3. Integrin 
immunohistochemistry on paraffin embedded 7 μm sections were stained with mouse monoclonal antibodies from BD-
Pharmingen, USA at a dilution of 1:200. Positive CD31 and Beta 3 showed dark brown and intense orange-brown staining, 
respectively. Each tumor section was counterstained with hemotoxylin.Molecular Cancer 2006, 5:5 http://www.molecular-cancer.com/content/5/1/5
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Practical applications
Preclinical studies have shown that the angiogenic switch
occurs early in the multi-step stage of cancer develop-
ment, which is required for tumor growth and metastasis
[34]. The intercellular junctions of endothelial cells con-
trol the intake and release of local agents, which is an inte-
gral factor in therapeutic gene delivery. This methodology
makes possible to study the factors that regulate angiogen-
esis progression and tumor regression.
In vivo labeling of endothelial cells using RCA-lectin can
play a pivotal role in the discovery of new organ specific
molecular markers and vascular targeted therapies. Ribatti
et al. has suggested that one problem in defining organ-
specific endothelial cell markers is due to the impurity of
endothelial cell used for in vitro analysis and to the lack
of organ specific markers of endothelial cells in culture
[35]. Indeed, our study provides a solution in that laser
capture microdissection guided by in vivo labeling of vas-
culature can produce homogenous cell populations from
endothelial cells and could identify organ specific
endothelial cell markers. Also, labeling of functional
endothelium with lectin could provide information about
cell-cell interactions within the host environment that
contribute to the induction and maintenance of ang-
iogenic factors. RCA binding may indicate that extracellu-
lar matrix components regulate endothelial cell surface D-
galactosyl residues, lymphocytes and metastatic tumor
cells. In vivo labeling of endothelial cells combined with
LCM can provide information about the metastatic poten-
tial of angiogenic vessels based on the specificity of lectin
binding. The parameters of this in vivo study, including
the brief circulation period of RCA-lectin would be ideal
for identifying functional and angiogenic vessels during
tumor biopsies to better characterize the tissue.
Conclusion
Our present study demonstrates that in vivo Rhodamine
RCA angiogenic vessel labeling provided a practical
approach to effectively guide functional endothelial cell
isolation by laser capture microdissection with fluores-
cent microscopy, resulting in high quality RNA and pure
samples of endothelial cells pooled for detecting genomic
expression.
Abbreviations
IHC, immunhistochemistry; RCA, Ricinus communis agglu-
tinin I;  LCM, laser capture microdissection; RT-PCR,
reverse transcription-polymerase chain reaction.
Acknowledgements
Ms. Finie Hunter was supported by the Intramural Research Training 
Award (IRTA) Program granted by the National Institutes of Health.
References
1. Fend F, Specht K, Kremer M, Quintanilla-Martinez L: Laser capture
microdissection in pathology.  Methods Enzymol 2002,
356:196-206.
2. Cantz T, Jochheim A, Cieslak A, Hillemann T, Scharf J, Manns MP, Ott
M: PCR based quantification of amplified RNA from laser
microdissected mouse liver samples.  Experimental and Molecular
Pathology 2003, 75:53-57.
3. BC Decker Inc: Novel Technologies for Identification of
Metastasis and Invasion-Promoting Genes and Gene Prod-
ucts:.  Cancer Medicine 5th edition. 2000.
4. Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg
PS, Petricoin EF 3rd: New approaches to proteomic analysis of
breast cancer.  Proteomics 2001, 1:1205-1215.
5. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin
EF 3rd: Proteomic analysis and identification of new biomar-
kers and therapeutic targets for invasive ovarian cancer.  Pro-
teomic 2002, 2:76-84.
6. Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke
CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF 3rd,
Emmert-Buck MR: Proteomic analysis of laser capture micro-
dissected human prostate cancer and in vitro prostate cell
lines.  Electrophoresis 2000, 21:2235-2242.
7. Leethanakul C, Patel V, Gillespie J, Shillitoe E, Kellman RM, Ensley JF,
Limwongse V, Emmert-Buck MR, Krizman DB, Gutkind JS: Gene
expression profiles in squamous cell carcinomas of the oral
cavity: use of laser capture microdissection for the construc-
tion and analysis of stage-specific cDNA libraries.  Oral Onco
2000, 36:474-83.
8. Leethanakul C, Patel V, Gillespie J, Pallente M, Ensley JF, Koontong-
kaew S, Liotta LA, Emmert-Buck M, Gutkind JS: Distinct pattern of
expression of differentiation and growth-related genes in
squamous cell carcinomas of the head and neck revealed by
the use of laser capture microdissection and cDNA arrays.
Oncogene 2000, 19:3220-3224.
9. Sugiyama Y, Sugiyama K, Hirai Y, Akiyama F, Hasumi K: Microdissec-
tion is essential for gene expression profiling of clinically
resected cancer tissues.  Am J Clin Pathol 2002, 117:109-116.
10. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R,
Cherish DA: Tumor Regression by Targeted Gene Delivery to
the Neovasculature.  Science 2002, 296:2404-2407.
11. Siemann DW, Horsman MR: Targeting the tumor vasculature: a
strategy to improve radiation therapy.  Expert Rev Anticancer
Ther 2004, 4:321-327.
12. Ruoslahti E: Specialization of Tumour Vasculature.  Nature
Reviews Cancer 2002, 2:83-90.
13. Wary KK: Molecular Targets for anti-angiogenic therapy.  Curr
Opin Mol Ther 2004, 6:54-70.
14. Thorpe PE: Vascular targeting agents as cancer therapeutics.
Clinical Cancer Research 2004, 10:415-427.
15. Segal MS, Bihorac A, Koc M: Circulating endothelial cell: tea
leaves for renal disease.  Am J Ren Physiology 2002, 283:F11-F19.
16. Gottesman M: Cancer Gene therapy: an awkward adoles-
cence.  Cancer Gene Therapy 2003, 10:501-508.
17. Carter P, Smith L, Ryan M: Identification and validation of cell
surface antigens for antibody targeting in oncology.  Endocrine-
Related Cancer 2004, 11:659-687.
18. Morabito A, Sarmiento R, Bonginelli P, Gasparini G: Antiangiogenic
strategies, compounds, and early clinical results in breast
cancer.  Critical Reviews in Oncology/Hematology 2004, 49:91-107.
19. Miettinen M, Lindenmayer AE, Chaubal A: Endothelial cell mark-
ers CD31, CD34, and BNH9 antibody to H- and Y-antigens--
evaluation of their specificity and sensitivity in the diagnosis
of vascular tumors and comparison with von Willebrand fac-
tor.  Modern Pathology 1994, 1:82-90.
20. Feng D, Nagy JA, Pyne K, Dvorak HF, Dvorak AM: Ultrastructural
localization of platelet endothelial cell adhesion molecule
(PECAM-1, CD31) in vascular endothelium.  J Histochem Cyto-
chem 2004, 52:87-101.
21. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM:
Origin of endothelial progenitors in human postnatal bone
marrow.  J Clin Invest 2002, 109:337-346.
22. Fukumoto M: Histochemical study using lectin and anti-human
von Willebrand factor antibody of oral hemangioma.  Nichidai
Koko Kagaku 1989, 15(4):431-40.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2006, 5:5 http://www.molecular-cancer.com/content/5/1/5
Page 11 of 11
(page number not for citation purposes)
23. Mojsilovic-Petrovic J, Nesic M, Pen A, Zhang W, Stanimirovic D:
Development of rapid staining protocols for laser capture
microdissection of brain vessels from human and rat coupled
to gene expression analysis.  Journal of Neuroscience Methods 2004,
133:39-48.
24. Fend F, Emmert-Buck MR, Chuaqui R, Cole K, Lee J, Liotta LA, Raffeld
M: Immuno-LCM: laser capture microdissection of immu-
nostained frozen sections for mRNA analysis.  American Journal
of Pathology 1999, 154:61-66.
25. Mikulowska-Meenis A, Taylor TB, Vishnu P, Michie SA, Raja R,
Horner N, Kunitake ST: High-quality RNA from cells isolated by
laser capture microdissection.  Biotechniques 2002, 33:176-179.
26. Murakami H, Liotta L, Star RA: IF-LCM: Laser capture microdis-
section of immunofluorescently defined cells for mRNA
analysis.  Kidney International 2000, 58:1346-1353.
27. Gerhart DZ, Zlonis MS, Drewes LR: Light and electron micro-
scopic localization of D-galactosyl residues in capillary
endothelial cells of the canine cerebral cortex.  The Histochem-
istry Society 1986, 34(5):641-648.
28. Freitas RA: Nanomedicine.  In Basic Capabilities, Landes Bioscience
Volume I. Georgetown, TX; 1999. 
29. Chang YS, di Tomaso E, McDonald DM, Jones R, Jain RK, Munn L:
Mosaic blood vessels in tumors: Frequency of cancer cells in
contact with flowing blood.  Medical Sciences 2000,
97:14608-14613.
30. Kohda Y, Murakami H, Moe OW, Star RA: Analysis of segmental
renal gene expression by laser capture microdissection.  Kid-
ney Int. 2000, 57(1):321-31.
31. Zhang W, Mojsilovic-Petrovic J, Andrade MF, Zhang H, Ball M, Stan-
imirovic DB: Expression and functional characterization of
ABCG2 in brain endothelial cells and vessels.  The FASEB Journal
2003. 10.1096/fj.02-1131fje
32. Crowe DL, Milo GE, Shuler CF: Keratin 19 downregulation by
oral squamous cell carcinoma lines increases invasive poten-
tial.  J Dent Res 1999, 78:1256-1263.
33. Lussier M, Filion M, Compton JG, Nadeau JH, Lapointe L, Royal A:
The mouse keratin 19 encoding gene; sequence, structure
and chromosomal assignment.  Gene 1990, 95:203-213.
34. Culp LA, Lin WC, Kleinman NR, Campero NM, Miller CJ, Holleran JL:
Tumor progression, micrometastasis, and genetic instability
tracked with histochemical marker genes.  Prog Histochem Cyto-
chem 1998, 33:329-348.
35. Ribatti D, Nico B, Vacca A, Roncali L, Dammacco F: Endothelial
Cell Heterogeneity and Organ Specificity.  J Hematother Stem
Cell Res 2002, 11(1):81-90.